Fig. 6

Expression of PAWR predicts prognosis of ovarian cancer. a Immunohistochemical staining for PAWR in 12 ovarian cancer tissues and paired normal fallopian tubes (Student’s t-test; bar, 20 μm). PAWR expression was also evaluated in another 38 clinical samples. The median HSCORE was used as the expression cut-off to classify patients into two subgroups (HSCORE ≤ 1, low expression; HSCORE > 1, high expression). Survival analysis was performed to compare these two groups, and survival curves were depicted for OS (b) and PFS (c) (log-rank test). According to the recurrence status within 6 months of completion of first-line treatment, patients were divided into two subgroups (recurrence within 6 months, resistant; no recurrence within 6 months, sensitive). d PAWR expression was compared between the sensitive group and the resistant group. (Student’s t-test; bar, 20 μm). P value was denoted as *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001